While AstraZeneca has announced that it will participate in the 2026 JP Morgan Healthcare Conference, it hasn’t yet revealed details about its presentation. At the 2025 conference, the company detailed the company’s performance during the first three quarters of 2024. According to the CFO, this success due to efforts to expand its clinical pipeline. Later…
Shots: EirGenix has entered into a strategic collaboration and non-exclusive licensing agreement with Transcenta for its Highly Intensified Continuous Bioprocessing (HiCB) platform Under the agreement, Transcenta will grant EirGenix a non-exclusive license to its HiCB platform, incl. continuous perfusion & integrated hybrid continuous purification process technologies, as well as documentation, know-how & regulatory support to…
Newly improved formulations of best-selling drugs can help to stave off the sales losses associated with the patent cliff to some degree. Image credit: Bahtiar Maulanaa via ShutterStock.com. As the looming patent cliff approaches, some major blockbuster drugs are set to lose their exclusivity, with pharma companies making moves to try and reduce the impact….
Intas partners IntegriMedical for needle-free injections in IVF and gynaecology – Express Pharma Home Latest Updates Intas partners IntegriMedical for needle-free injections in IVF and gynaecology Source link
In many ways, it’s been a banner year for chronic disease. America’s enduring ailments became a central theme of the Trump administration, with health secretary Robert F. Kennedy Jr. wielding his influence over the president. Trump created a commission focused on childhood chronic illnesses, which issued two reports on the matter. Statehouses across the country…
MSI-H/dMMR colon cancer comprises 15% of resectable cases and responds poorly to chemotherapy. Credit: NMK-Studio/Shutterstock.com. Innovent Biologics has received China’s National Medical Products Administration (NMPA) approval for the New Drug Application (NDA) for Tabosun (ipilimumab N01 injection), a CTLA-4 monoclonal antibody for colon cancer. The approval covers its use in combination with sintilimab as a…
Pharma Outlook 2026: India’s leap from ‘World’s Pharmacy’ to ‘World’s Innovation Partner’ – Express Pharma Home Latest Updates Pharma Outlook 2026: India’s leap from ‘World’s Pharmacy’ to ‘World’s Innovation Partner’ Source link
Shots: Chinese NMPA received two IND applications for CT0596 to initiate P-Ib/II trials in r/r multiple myeloma (MM) & primary plasma cell leukemia (pPCL), respectively IIT in China showed favorable efficacy as of Aug 31, 2025, with 6/8 evaluable R/R MM pts achieving PR or better (3 CR/sCR, 1 VGPR, 2 PR) at an mFU…
Shots: Harbour BioMed has entered into a long-term strategic collaboration with Yantai Lannacheng Biotechnology to jointly advance the development of next-generation RDCs Collaboration will combine Harbour’s fully human antibody discovery capabilities via its Harbour Mice platform with Lannacheng’s radiopharmaceutical R&D & commercialization strengths Harbour Mice platform provides fully human mAbs in both conventional & heavy chain-only…
Shots: ABL Bio has secured a total of $55M, incl. $40M upfront & $15M in equity investment, from Eli Lilly under their ~$2.602B license, research & collaboration agreement Under the deal, ABL Bio & Eli Lilly are jointly advancing multiple therapeutic candidates across diverse modalities, leveraging ABL Bio’s Grabody platform for collaborative research & development…